Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin. Pemphigus ...

pemphigus vegetans, and paraneoplastic pemphigus, is based primarily on histology, serology, and clinical presentation. Other conditions that must be differentiated from PV and may present with ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Fewer than 10% of children or adolescents with peanut allergy passed a desnsitiaztion food challenge after receiving dupilumab for 24 weeks. Image: Adobe Stock “The impact of the findings for ...

Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing course, with a potentially ...

Dupilumab vs conventional AD therapies had less risk for anxiety, depression, and adjustment and sleep disorders, especially among Black patients. Patients with atopic dermatitis (AD) who were ...

They collected skin tape strips (STS) from the lesional and non-lesional skin of 20 patients with AD and 20 healthy volunteers (HV) over 16 weeks of dupilumab treatment. STS extracts were analyzed ...

Introduction: The autoantibody-driven disease pemphigus vulgaris (PV) impairs desmosome adhesion in the epidermis. In desmosomes, the pemphigus autoantigens desmoglein 1 (Dsg1) and Dsg3 link adjacent ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

These “remote effects” or paraneoplastic manifestations of cancer include metabolic and endocrine syndromes such as hypercalcaemia, and the syndrome of inappropriate ADH (antidiuretic hormone) ...